MY158800A - Composition - Google Patents
CompositionInfo
- Publication number
- MY158800A MY158800A MYPI2010001917A MYPI2010001917A MY158800A MY 158800 A MY158800 A MY 158800A MY PI2010001917 A MYPI2010001917 A MY PI2010001917A MY PI2010001917 A MYPI2010001917 A MY PI2010001917A MY 158800 A MY158800 A MY 158800A
- Authority
- MY
- Malaysia
- Prior art keywords
- mbp
- composition
- relates
- treat
- disease
- Prior art date
Links
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 abstract 1
- 102000047918 Myelin Basic Human genes 0.000 abstract 1
- 101710107068 Myelin basic protein Proteins 0.000 abstract 1
- 206010029240 Neuritis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Marine Sciences & Fisheries (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Confectionery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0721430A GB0721430D0 (en) | 2007-10-31 | 2007-10-31 | Composition |
| GB0800962A GB0800962D0 (en) | 2008-01-18 | 2008-01-18 | Conposition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY158800A true MY158800A (en) | 2016-11-15 |
Family
ID=40591554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2010001917A MY158800A (en) | 2007-10-31 | 2008-10-30 | Composition |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US8623827B2 (enExample) |
| EP (1) | EP2211892B1 (enExample) |
| JP (1) | JP5361895B2 (enExample) |
| KR (1) | KR101570383B1 (enExample) |
| CN (1) | CN101848725B (enExample) |
| AT (1) | ATE518546T1 (enExample) |
| AU (1) | AU2008320657B2 (enExample) |
| BR (1) | BRPI0818302B1 (enExample) |
| CA (1) | CA2703170C (enExample) |
| CY (1) | CY1112620T1 (enExample) |
| DK (1) | DK2211892T3 (enExample) |
| EA (1) | EA017999B1 (enExample) |
| EC (1) | ECSP10010211A (enExample) |
| HR (1) | HRP20110724T1 (enExample) |
| IL (1) | IL204662A (enExample) |
| MX (1) | MX2010004698A (enExample) |
| MY (1) | MY158800A (enExample) |
| NZ (1) | NZ583924A (enExample) |
| PL (1) | PL2211892T3 (enExample) |
| PT (1) | PT2211892E (enExample) |
| SI (1) | SI2211892T1 (enExample) |
| WO (1) | WO2009056833A2 (enExample) |
| ZA (1) | ZA201001748B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030062321A (ko) * | 2000-08-21 | 2003-07-23 | 아피토프 테크놀러지 (브리스톨) 리미티드 | 펩티드 선별 방법 |
| KR101570383B1 (ko) | 2007-10-31 | 2015-11-19 | 아피토프 테크놀러지 (브리스톨) 리미티드 | 조성물 |
| JP5709876B2 (ja) | 2009-10-12 | 2015-04-30 | ライフバイオ ラボラトリーズ エルエルシーＬＩＦＥＢｉｏ ＬＡＢＯＲＡＴＯＲＩＥＳ ＬＬＣ | 多発性硬化症治療用組成物 |
| GB201300684D0 (en) * | 2013-01-15 | 2013-02-27 | Apitope Int Nv | Peptide |
| GB201603582D0 (en) * | 2016-03-01 | 2016-04-13 | Apitope Int Nv | Peptides |
| WO2018127828A1 (en) * | 2017-01-04 | 2018-07-12 | Apitope International Nv | Therapeutic method using tolerogenic peptides |
| GB201700095D0 (en) * | 2017-01-04 | 2017-02-22 | Apitope Int Nv | Composition |
| JP7419229B2 (ja) * | 2017-08-14 | 2024-01-22 | 百明信康生物技術（浙江）有限公司 | 方法 |
| IL307722A (en) | 2021-04-16 | 2023-12-01 | Cour Pharmaceuticals Dev Company Inc | A method of monitoring the existence of immunological tolerance |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5817629A (en) | 1991-10-22 | 1998-10-06 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
| KR20030062321A (ko) * | 2000-08-21 | 2003-07-23 | 아피토프 테크놀러지 (브리스톨) 리미티드 | 펩티드 선별 방법 |
| US20040096456A1 (en) | 2000-12-01 | 2004-05-20 | Conti-Fine Bianca M | Method to treat hemophilia |
| GB0202399D0 (en) * | 2002-02-01 | 2002-03-20 | Univ Bristol | Peptide |
| KR101570383B1 (ko) | 2007-10-31 | 2015-11-19 | 아피토프 테크놀러지 (브리스톨) 리미티드 | 조성물 |
-
2008
- 2008-10-30 KR KR1020107005853A patent/KR101570383B1/ko active Active
- 2008-10-30 MY MYPI2010001917A patent/MY158800A/en unknown
- 2008-10-30 US US12/740,976 patent/US8623827B2/en active Active
- 2008-10-30 HR HR20110724T patent/HRP20110724T1/hr unknown
- 2008-10-30 EP EP08844568A patent/EP2211892B1/en active Active
- 2008-10-30 PT PT08844568T patent/PT2211892E/pt unknown
- 2008-10-30 EA EA201070541A patent/EA017999B1/ru not_active IP Right Cessation
- 2008-10-30 AU AU2008320657A patent/AU2008320657B2/en active Active
- 2008-10-30 SI SI200830411T patent/SI2211892T1/sl unknown
- 2008-10-30 WO PCT/GB2008/003673 patent/WO2009056833A2/en not_active Ceased
- 2008-10-30 JP JP2010530555A patent/JP5361895B2/ja active Active
- 2008-10-30 NZ NZ583924A patent/NZ583924A/en unknown
- 2008-10-30 DK DK08844568.9T patent/DK2211892T3/da active
- 2008-10-30 CA CA2703170A patent/CA2703170C/en active Active
- 2008-10-30 BR BRPI0818302-3A patent/BRPI0818302B1/pt active IP Right Grant
- 2008-10-30 PL PL08844568T patent/PL2211892T3/pl unknown
- 2008-10-30 AT AT08844568T patent/ATE518546T1/de active
- 2008-10-30 MX MX2010004698A patent/MX2010004698A/es active IP Right Grant
- 2008-10-30 CN CN2008801138365A patent/CN101848725B/zh active Active
-
2010
- 2010-03-11 ZA ZA2010/01748A patent/ZA201001748B/en unknown
- 2010-03-22 IL IL204662A patent/IL204662A/en active IP Right Grant
- 2010-05-28 EC EC2010010211A patent/ECSP10010211A/es unknown
-
2011
- 2011-10-25 CY CY20111101006T patent/CY1112620T1/el unknown
-
2013
- 2013-12-06 US US14/099,463 patent/US9381234B2/en active Active
-
2016
- 2016-06-03 US US15/173,018 patent/US9775880B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL204662A0 (en) | Composition | |
| JOP20190083B1 (ar) | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها | |
| PH12015502433B1 (en) | Fgf21 mutants and uses thereof | |
| TN2011000161A1 (en) | Fgf21 mutants and uses thereof | |
| TW201129377A (en) | Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho | |
| MX2015011199A (es) | Agentes terapéuticos de csf1. | |
| MX2009012949A (es) | Anticuerpos humanizados que enlazan a ab (1-42) globulomero y usos de los mismos. | |
| MX2009009200A (es) | Tratamiento de enfermedades caracterizadas por la inflamacion. | |
| WO2009129246A3 (en) | Compositions and methods for preparing and using same | |
| EA201101521A1 (ru) | Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния | |
| WO2010151797A3 (en) | Compounds for modulating rna binding proteins and uses therefor | |
| HK1250737A1 (zh) | 结合cd79的抗体分子 | |
| WO2010064012A3 (en) | Treatment of autoimmune disease by modulating annexin-i (lipocortin 1 ) | |
| WO2008063849A3 (en) | Multiple sclerosis therapy | |
| EA201000903A1 (ru) | Антитела к pcrv-антигену pseudomonas aeruginosa | |
| WO2007075439A3 (en) | Compositions and methods for treating obesity and related metabolic disorders | |
| WO2009138494A3 (en) | Amino acid sequences directed against toll-like receptors and their use for the treatment of diseases related to toll-like receptors | |
| WO2009137795A3 (en) | Methods for treating endoplasmic reticulum (er) stress disorders | |
| MX2012004295A (es) | Composicion para el tratamiento de esclerosis multiple. | |
| WO2008005470A3 (en) | Polypeptides that bind membrane proteins | |
| WO2010046461A3 (en) | Treatment of intracellular bacterial infections | |
| WO2010041827A3 (en) | NF-κB INHIBITOR CONTAINING ARH1 PROTEIN OR GENE ENCODING THE SAME | |
| WO2007044989A3 (en) | Modulators of nod1 signaling | |
| UA102395C2 (en) | Fgf21 mutants and use thereof | |
| UA107458C2 (uk) | Мутанти fgf21 та їх застосування |